Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma
Learn more about:
Related Access Program
British Columbia Cancer Agency – Pheochromocytoma
Molecular Insight Pharmaceuticals, Inc. – Pheochromocytoma
Children’s Hospital of Philadelphia – Pheochromocytoma
Jubilant DraxImage Inc. – Pheochromocytoma
Children’s Hospital Medical Center, Cincinnati – Pheochromocytoma
University of California, San Francisco – Pheochromocytoma
Related Clinical Trial
The Effect and Safety of Omitting Preoperative Alpha-adrenergic Blockade for Normotensive Pheochromocytoma
Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors
In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma
Predictors and Outcomes of Dysglycemia in Pheochromocytoma and Paraganglioma
Cardiac and Vascular Changes in Pheochromocytoma and Paraganglioma
Metanephrines in Obstructive Sleep Apnoea
Plasma Metanephrines in Patients With Cyanotic and Acyanotic Congenital Heart Disease
Development of a Predictive Model for the Risk of Metastatic Disease in PPGLs, a Retrospective Cohort Study
Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
Infrared Thermography Associated With Cutaneous Microcirculation for Detection of Brown-adipose Tissue (MICROBAT)
Development of a Tele-monitoring Program for Patients Undergoing Surgery for Pheochromocytoma and / or Paraganglioma
Pheochromocytoma and Hemodynamic Instability
Selective Versus Nonselective Alpha-blockade Prior to Pheochromocytoma Resection – Systematic Review and Meta-analysis
Prevention of Conversion in Posterior Retroperitoneal Adrenalectomy by Measuring Preoperative Anatomical Conditions
Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors
Efficacy and Safety of Posterior Retroperitoneoscopic Adrenalectomy: A Comparative Study
Blood Sampling for Neurochemical and Genetic Testing
Hereditary Paraganglioma: Evaluation of Screening Methods to Detect Tumors in SDH Positive Carriers
Dosimetry Guided PRRT With 177Lu-DOTATATE in Children
Expanded Access Protocol Using 131I-MIBG
Dovitinib in Neuroendocrine Tumors
Effect of Chronic Catecholamine Overproduction on Brown Adipose Tissue
A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer
ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid
Expanded Access Protocol Using 131I-MIBG Therapy for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma
Non-invasive Evaluation of Fluid Status and Cardiac Output During Operative Treatment of Pheochromcytoma
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET)
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma
Preoperative Alpha Blockade for Pheochromocytoma
Phenoxybenzamine Versus Doxazosin in PCC Patients
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid
Multicenter Pheochromocytoma and Paraganglioma Evaluation
A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma
Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma
Comparison of Diagnostic Performances of 68Ga-DOTATATE PET-CT and 18F-FDOPA PET-CT in Paragangliomas and Pheochromocytomas Evaluation
Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma
Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma
Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma
A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma
Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma
Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma
A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma
18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma
A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors
Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma
131MIBG to Treat Malignant Pheochromocytoma
Content Validation of Quality of Life and Symptom Questionnaires for Pheochromocytoma and Paraganglioma
Diagnosis and Treatment of Pheochromocytoma
the Effect of Dexmedetomidine and Magnesium Sulfate in Open Resection of Pheochromocytoma
LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA)
I-123-MIBG for Imaging of Neuroblastoma and Pheochromocytoma
Surgeon-Anesthesiologist Collaboration
Diagnosis of Pheochromocytoma
Specificity of Elevated Plasma EM66 Levels in Pheochromocytoma